New Zealand markets closed

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
10.86+0.36 (+3.43%)
At close: 04:00PM EDT
10.69 -0.17 (-1.57%)
After hours: 07:18PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.50
Open10.50
Bid10.82 x 200
Ask10.90 x 100
Day's range10.30 - 11.40
52-week range4.78 - 42.60
Volume428,641
Avg. volume762,576
Market cap228.052M
Beta (5Y monthly)1.25
PE ratio (TTM)0.94
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

    LEXINGTON, Mass., May 16, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensilimab plus balstilimab (BOT/BAL) combination therapy studies in patients with relapsed/refractory metastatic colorectal cancer that is not MSI-high or dMMR (r/r MSS mCRC), as well as the

  • Business Wire

    Agenus Reports First Quarter 2024 Results

    LEXINGTON, Mass., May 07, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024. In a concurrent press release accompanying Agenus’ earnings announcement, a $100M royalty financing agreement between Ligand and Agenus was reported. This pivotal, minimally dilutive capital infusion will support the key development and launch readiness initiatives needed to advance t

  • Business Wire

    Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

    JUPITER, Fla. and LEXINGTON, Mass., May 07, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with met